Contribution of NK cells to immunotherapy mediated by PD-1/PD-L1 blockade-Reference-Cited by-同舟云学术

Contribution of NK cells to immunotherapy mediated by PD-1/PD-L1 blockade

Published:2018-09-10 Issue:10 Volume:128 Page:4654-4668
ISSN:0021-9738
Container-title:Journal of Clinical Investigation
language:en
Short-container-title:

Author:

Hsu Joy,Hodgins Jonathan J.,Marathe Malvika,Nicolai Chris J.,Bourgeois-Daigneault Marie-Claude^ORCID,Trevino Troy N.,Azimi Camillia S.,Scheer Amit K.,Randolph Haley E.,Thompson Thornton W.,Zhang Lily,Iannello Alexandre,Mathur Nikhita,Jardine Karen E.,Kirn Georgia A.,Bell John C.,McBurney Michael W.,Raulet David H.,Ardolino Michele

Publisher

American Society for Clinical Investigation

Subject

General Medicine

Link

https://www.jci.org/articles/view/99317/files/pdf

Reference78 articles.

1. Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer

2. Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer

3. Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma

4. CTLA-4 and PD-1 pathway blockade: combinations in the clinic;Callahan;Front Oncol,2014

5. Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial

Cited by 589 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Deciphering single-cell transcriptomic landscape of tumors in colorectal cancer treated with photothermal semiconducting polymers to design the combination therapy with checkpoint blockades for inhibition of tumor progression and metastasis;Nano Today;2024-10

2. Cell Identity and Spatial Distribution of PD‐1/PD‐L1 Blockade Responders;Advanced Science;2024-09-09

3. Inverse correlation between TP53 gene status and PD-L1 protein levels in a melanoma cell model depends on an IRF1/SOX10 regulatory axis;Cellular & Molecular Biology Letters;2024-09-05

4. Metabolic reprogramming and immune evasion: the interplay in the tumor microenvironment;Biomarker Research;2024-09-03

5. Reprogramming natural killer cells for cancer therapy;Molecular Therapy;2024-09